logo
  

Shell To Take Up To $22 Bln Charges In Q2 - Quick Facts

Royal Dutch Shell plc (RDS-B,RDSB.L,RDSA.L,RDS-A) said it expects post-tax impairment charges to be in the range of $15 billion to $22 billion in the second quarter, after revising its outlook for commodity prices and margin outlook amid the Covid-19 pandemic.

The impairments are expected to have a pre-tax impact in the range of $20 billion to $27 billion. No impairment charge on Goodwill is expected to be recorded in the second quarter, the company said.

In integrated Gas, the company expects production to be between 880 and 910 thousand barrels of oil equivalent per day; LNG liquefaction volumes of 8.1 million tonnes and 8.5 million tonnes.

In upstream, production is expected to be between 2,300 and 2,400 thousand barrels of oil equivalent per day.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
Follow RTT